Bile Duct Cancer: Diagnosis

The Government is committed to improving outcomes for people affected by rare and less common cancers, including cholangiocarcinoma.

The National Cancer Plan for England identifies earlier diagnosis as a key priority and includes specific commitments to improve outcomes for rare and less common cancers. The plan sets out action to expand diagnostic capacity, improve access to tests and scans, and reduce the number of cancers diagnosed through emergency presentation.

Full roll out of non-specific symptom (NSS) pathways has been achieved across England. NSS pathways are designed to speed up the diagnosis of cancer by providing a route to possible diagnosis for patients whose symptoms may indicate cancer but do not align with a specific tumour type. This is particularly important for rare cancers such as cholangiocarcinoma, which can present with NSS’ and may be diagnosed at a later stage.

The National Cancer Plan makes clear that improving outcomes for rare and less common cancers is a priority, and includes action to improve care and outcomes across the cancer pathway, from earlier diagnosis through to treatment and ongoing support. Central to this is strengthening clinical leadership, including the appointment of a national lead for rare cancers to provide expert advice and drive improvements in care.

The National Institute for Health and Care Excellence is responsible for developing evidence-based clinical guidance for the health and care system. The Department continues to work with partners across the cancer community to improve diagnosis, treatment, and outcomes for people affected by rare and less common cancers like cholangiocarcinoma.